Document Detail


Oxygen toxicity in premature infants.
MedLine Citation:
PMID:  12030843     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxygen causes tissue injury through the formation of reactive oxygen intermediates and peroxidation of membrane lipids. Premature infants, who have severely reduced antioxidant defenses, are particularly sensitive to the toxic effects of oxygen. Supplemental oxygen in premature infants contributes to the development of chronic lung disease (bronchopulmonary dysplasia), characterized by dysregulated inflammation and altered expression of proteases and growth factors. This can result in fibrosis, asymmetric aeration, and respiratory insufficiency. Oxygen also induces aberrant physiologic responses that can be damaging in premature infants. For example, vasoconstriction in the retina is an early response to oxygen that can lead to vasoobliteration, neovascularization, and retinal traction (retinopathy of prematurity). Increasing knowledge of the mechanisms underlying oxygen toxicity in premature infants has suggested strategies to minimize tissue injury and to optimize long-term medical outcomes. These include limiting oxygen supplementation and light exposure, the use of antiinflammatory agents or antioxidants, and the use of room air in neonatal resuscitation.
Authors:
Barry Weinberger; Debra L Laskin; Diane E Heck; Jeffrey D Laskin
Related Documents :
22633503 - Fluconazole use and safety in the nursery.
602753 - Oxygen therapy and massive pulmonary haemorrhage in newborn infants.
22110293 - The factors contributing to the risk of sudden infant death syndrome.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Toxicology and applied pharmacology     Volume:  181     ISSN:  0041-008X     ISO Abbreviation:  Toxicol. Appl. Pharmacol.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-05-28     Completed Date:  2002-06-26     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0416575     Medline TA:  Toxicol Appl Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  60-7     Citation Subset:  IM    
Copyright Information:
(c) 2002 Elsevier Science (USA).
Affiliation:
Department of Pediatrics/Neonatology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antioxidants / metabolism,  therapeutic use
Bronchopulmonary Dysplasia / etiology,  pathology,  prevention & control
Chronic Disease
Humans
Infant, Newborn
Infant, Premature*
Oxygen Inhalation Therapy / adverse effects*
Retinopathy of Prematurity / etiology,  pathology,  prevention & control
Chemical
Reg. No./Substance:
0/Antioxidants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme ex...
Next Document:  Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligo...